Arrowhead price target raised to $85 from $80 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $85 from $80 and keeps a Buy rating on the shares. The firm says the company’s “transformative” fiscal Q4 was driven by FDA approval of Redemplo for familial chylomicronemia syndrome. This marks an “inflection point” for Arrowhead’s RNA interference pipeline, the analyst tells investors in a research note. H.C. Wainwright cites increased conviction that Arrowhead is entering a sustained period of clinical, regulatory, and commercial value creation for the target bump.